Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Seletalisib shows therapeutic potential in primary Sjögren’s syndrome

19 Oct 2020

The selective PI3Kδ inhibitor seletalisib demonstrates clinical activity in patients with primary Sjögren’s syndrome (PSS) despite enrolment-related underpowering, as shown in phase II trial data.

In total, 27 patients with moderate-to-severe PSS were randomized to treatment with either seletalisib 45 mg/day (n=13; mean age, 52.2 years; 12 women) or placebo (n=14; mean age, 60.2 years; 13 women); 20 of them completed the study. The trial was terminated prematurely due to enrolment challenges with loss of statistical power (36 percent vs 80 percent planned).

At week 12, both arms showed a change in EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) score, but the reduction was greater with the study drug (difference, –2.59, 95 percent confidence interval [CI], –7.30 to 2.11; p=0.266). The change seen in EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) score was also greater with seletalisib (difference, –1.55, 95 percent CI, –3.39 to 0.28).

There were no significant changes in saliva and tear flow.

In terms of safety, serious adverse events (AEs) developed in 3/13 of patients on seletalisib vs 1/14 of those on placebo. AEs led to treatment discontinuation in five and one patients, respectively. The most common event was diarrhoea.

Serum IgM and IgG concentrations markedly dropped in the seletalisib arm. The study drug produced an improvement in size and organization of salivary gland inflammatory foci and in target engagement, which therefore reduced PI3K-mTOR signaling compared with placebo.

Larger studies with specific PI3Kδ inhibitors and, potentially, with patient stratification are needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.